Drugs / Anbalcabtagene autoleucel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04836507 | Mar 2021 → Aug 2030 expected | B-cell acute lymphoblastic leukemia, follicular lymphoma, high grade B-cell lymphoma, large B-cell lymphoma +1 | Curocell Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anbalcabtagene autoleucel | “Anbalcabtagene autoleucel (Anbal-cel) is a CD19-directed CAR T-cell therapy incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability.” PMID 42284198 ↗ Jun 2026 |
| Known as | Anbal-cel | “Anbalcabtagene autoleucel (Anbal-cel) is a CD19-directed CAR T-cell therapy incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability.” PMID 42284198 ↗ Jun 2026 |
| Action | Inhibit | “incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability” PMID 42284198 ↗ Jun 2026 |
| Modality | Cell therapy | “Anbalcabtagene autoleucel (Anbal-cel) is a CD19-directed CAR T-cell therapy” PMID 42284198 ↗ Jun 2026 |
| Route | Intravenous | “administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg” NCT04836507 ↗ |
| Target | TIGIT | “Anbalcabtagene autoleucel (Anbal-cel) is a CD19-directed CAR T-cell therapy incorporating dual PD-1 and TIGIT knockdown” PMID 42284198 ↗ Jun 2026 |